A number of preclinical experiments designed to express genes in CNS neurons have employed viral vectors that can directly infect these post-mitotic cells, eg a lentiviral vector, [1] [2] [3] or an AAV vector. [4] [5] [6] These studies are directed towards restoring in vivo the function of neurons that have been affected by an acquired or inherited disease. In the case of Parkinson's disease, in particular, an alternative approach has involved neuronal replacement using fetal brain tissue. 1, [7] [8] [9] Successful isolation of stem cells from both human adult and fetal brains, and their expansion in vitro [10] [11] [12] [13] [14] promise to increase the availability of such non-autologous neurons. On the other hand, autologous neural stem cells may ultimately be obtainable; it has been reported that cells derived from bone marrow and skin can differentiate into neurons. [15] [16] [17] [18] [19] For both research and therapeutic purposes, it would be useful to have a safe and efficient means to genetically manipulate neural stem cells. A gammaretrovirus-based vector constitutes an obvious choice as it is well documented that such vectors can transduce these slowly dividing cells, 20 both in vivo 21, 22 and in vitro. 10, 23 Work with hematopoietic stem cells has led to the development of improved gammaretroviral vectors, and many of these vectors are based on the murine embryonic stem cell virus [24] [25] [26] [27] that was originally developed to infect embry- onic stem cells. 28 We have focused on making a derivative of this virus that may be particularly useful for genetically modifying neural stem cells.
In previous work, 29 both the upstream and downstream long terminal repeats (LTRs) of an MESV vector 30 were reconfigured such that the former contained a strong enhancer to drive production of viral RNA in packaging cells, and the latter could accommodate natural or synthetic tissue-specific enhancer elements to facilitate transcriptional targeting. In addition, the viral basal promoter in the downstream LTR was replaced with a strong synthetic basal promoter comprising an optimized TATA box and the initiator regulator from the Dntt gene. This manipulation also eliminated a number of the potential CpG methylation sites from the U3 region that may contribute to transcriptional silencing. 31, 32 Recent efforts to optimize gene expression from gammaretroviral vectors have focused on post-transcriptional events. [33] [34] [35] To enhance the efficiency and safety of the existing MESV vector, the transcribed leader region was extensively modified. The AUG located in the proximal region of the packaging/dimerization domain 33 could compete with that of the transgene for translation initiation, and, if utilized, could result in the synthesis of a potentially immunogenic peptide. This start codon was therefore mutated to GUG. The murine sarcoma virus, from which part of the transcribed leader of the MESV vector is derived, 30 does not express functional glycogag, an aminoterminal extension of the gag open reading frame. 36 However, sequence analysis indicated that a short peptide could be generated from the glycogag CUG start site, and therefore this CUG was changed to GUG. Since a stem loop that is critical to packaging is formed by the sequence encompassing the glycogag CUG, a compensating downstream base change was made in order to preserve the integrity of this structure. 37, 38 In some gammaretroviral vectors, efficient transgene 56 and vesicular stomatitis virus G glycoprotein. 57 Gene Therapy expression is tied to RNA splicing. 34, 39 However, it was previously reported that the constitutive transport element (CTE) from the Mason-Pfizer monkey virus could substitute for the presence of an intron in the 5' leader region and replace the endogenous CTE localized to the 5' end of the gag gene. 34, 35, 40 To replace the endogenous CTE, and to circumvent the possibility of recombination between the virus and a murine leukemia virus-derived gag-pol packaging plasmid, we inserted the recently defined CTE from avian leukemia virus (ALV) 41 immediately downstream of the packaging/ dimerization domain, replacing all of the extant gag sequences. Since the ALV CTE contains a single AUG that could potentially be used to translate a 19 amino acid peptide, this start site was also mutated. The changes that were made to the transcribed leader region of the virus are summarized in Figure 1 .
To determine whether the modified virus, designated MESV2, could be packaged into infectious virions, the enhanced green fluorescent protein (EGFP) gene was placed immediately downstream of the ALV CTE. In addition, the U3 enhancer region from Rous sarcoma virus (RSV) was inserted into the polylinker in the downstream LTR of the retroviral vector to drive gene expression in transduced cells. This vector was designated MESV2/EGFP/RSV. In order to verify the effectiveness of the ALV CTE, a second construct was made in which this sequence was removed. Recombinant virions, pseudotyped with VSV-G glycoprotein, were made by transient transfection of Cos 1 cells, and B104 neural tumor cells were subsequently infected. 42 The expression of EGFP was measured by flow cytometry 72 h after infection. Removal of the CTE reduced the number of B104 cells that were infected by~50%, and lowered the level of EGFP expression by~13% as shown by a decrease in mean fluorescence intensity (Figure 2 ). Since equal numbers of Cos 1 cells were transfected with equal amounts of the two retroviral plasmids, and the same number of cells were exposed to virus in both cases, we conclude that removal of the ALV CTE had a significant effect on viral titer. In gammaretroviruses, mutation of a sequence in the R region markedly reduces the accumulation of unspliced viral RNA in the cytoplasm. 43 This R region motif may facilitate the export of viral RNA even in the absence of a CTE, which could explain why EGFP expression was only partially decreased in those cells that were infected.
Although the RSV U3 enhancer is strongly active in Figure 2 except that virions were collected in neural stem cell medium. Three days after infection, the cultures were processed for immunocytochemistry as previously described. 49 many different cell types, it has been reported that longterm expression from the RSV LTR is suppressed in mammalian cells due to methylation. 44 On the other hand, the Pgk-1 gene is transcriptionally active in both differentiated and undifferentiated cells. 45, 46 We therefore made two additional viral vectors in which the downstream LTR contained either the upstream activator sequence from Pgk-1 in place of the RSV U3 region or sequences from the Syn1 promoter that confer neuronalspecific expression placed immediately upstream of a truncated Pgk-1 UAS. We reasoned that such a hybrid enhancer might drive higher levels of transcription in differentiated neurons than the Pgk-1 UAS alone. To test these two new vectors, designated MESV2/EGFP/Pgk and MESV2/EGFP/Syn⌬Pgk respectively, and to compare them to MESV2/EGFP/RSV, B104 cells were infected, and EGFP expression was analyzed by flow cytometry (Figure 3 ). Not unexpectedly, cells infected with MESV2/EGFP/RSV expressed the highest levels of EGFP compared with those infected with MESV2/EGFP/Pgk or MESV2/EGFP/Syn⌬Pgk. However the combination of Pgk-1 and Syn1 promoter sequences appeared to act as a stronger enhancer than the Pgk-1 UAS in B104 cells (Figure 3) .
Figure 4 MESV2 infection of neural stem cells and continued expression in differentiated neurons. (a) EGFP expression (green signal) in nestin + neural stem cells (red signal) following infection with MESV2/EGFP/Syn⌬Pgk. (b) EGFP expression (green signal) in ␤-tubulin

Cells were co-stained with an anti-nestin monoclonal antibody (BD Biosciences) and an anti-GFAP polyclonal antibody (Dako, Glostrup, Denmark). Nestin immunoreactivity was visualized with Texas red-conjugated goat anti-mouse polyclonal antibody and GFAP staining was visualized with Alexa-350-conjugated mouse anti-rabbit monoclonal antibody (Molecular Probes, Eugene, OR, USA
Primary neural stem cells were prepared from E16 rat hippocampi, and were infected with the three viruses described above under conditions that promote cell proliferation, but suppress neuronal differentiation. 49 After 72 h, cultures of infected cells were prepared for immunocytochemistry, and co-stained with a monoclonal antibody directed against nestin, an intermediate filament protein found in neural progenitors, 50 and a polyclonal antibody directed against glial fibrillary acidic protein (GAFP), an astrocyte marker. Figure 4a shows We focused on MESV2/EGFP/RSV and MESV2/ EGFP/Syn⌬Pgk, and in a second experiment, stem cells that had been infected with these viruses over 2 consecutive days were induced to differentiate. 51 After 2 weeks, cells were co-immunostained for tubulin ␤-III, a cytoskeletal component characteristic of differentiated neurons, and for GFAP. As shown in Figure 4b , EGFP expression persisted in cells following differentiation into neurons. We also obtained strong EGFP expression in astrocytes with both viruses (Figure 4b ). Cell counts indicated that 52.8% of the tubulin ␤-III + neurons expressed EGFP following infection of stem cells with MESV2/EGFP/RSV, and 30.8% of neurons expressed EGFP after infection of stem cells with MESV2/EGFP/Syn⌬Pgk. The percentages of infected nestin + cells in parallel cultures that had been exposed to the same batches of virus were 55.7% and 29%, respectively. It will be important to evaluate long-term gene expression by transplantating neural stem cells infected with these two viruses into animal models.
In summary, MESV2 is a modified stem cell virus designed to enhance transgene expression and increase vector safety. The modular nature of this vector readily allows the insertion or replacement of sequences in critical locations within the vector. Addition of a scaffold attachment region, 52 an insulator sequence, 27, 53 or a CpG island 54 to the LTR may help confer position-independent transgene expression; and insertion of synthetic internal ribosome entry sites 42, 55 will allow expression of multiple transgenes. We have here demonstrated the utility of MESV2 by expressing a marker gene in neurons derived from infected neural stem cells.
